Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer

被引：0
|
作者：
Kelly, R. [1 ]
Wong, S. S. L. [2 ]
Shapiro, J. [3 ]
Weickhardt, A. J. [4 ]
Parente, P. [5 ]
Azad, A. [6 ]
Uccellini, A. [7 ]
Torres, J. [8 ]
Parnis, F. [9 ]
Kwan, E. [10 ]
Brown, S. [11 ]
Steer, C. [12 ]
Warren, M. [13 ]
Gibbs, P. [14 ]
Anton, A. [1 ]
Tran, B. [1 ]
机构：
[1] Walter Eliza Hall Inst Med Res, Clin Data Clin Trials & Biomarkers, Parkville, Vic, Australia
[2] Sunshine Hosp Western Hlth, Med Affairs Dept, St Albans, Vic, Australia
[3] Alfred Hosp, Med Oncol, Melbourne, Vic, Australia
[4] Olivia Newton John Canc Wellness & Res Ctr, Dept Med Oncol, Heidelberg, Vic, Australia
[5] Box Hill Hosp, Eastern Hlth, Dept Med Oncol, Bldg B, Box Hill, Vic, Australia
[6] Peter MacCallum Canc Ctr, Dept Oncol, Melbourne, Vic, Australia
[7] Austin Hosp, Austin Hlth, Med Oncol, Heidelberg, Vic, Australia
[8] Goulburn Valley Hlth, Dept Med Oncol, Shepparton, Vic, Australia
[9] Adelaide Canc Ctr, Dept Med Oncol, Adelaide, SA, Australia
[10] Monash Canc Ctr, Monash Hlth, Med Oncol, Bentleigh East, Vic, Australia
[11] Ballarat Hlth Serv, Med Oncol, Ballarat Base Hosp, Ballarat, Vic, Australia
[12] Border Med Oncol, Dept Med Oncol, East Albury, Vic, Australia
[13] Bendigo Hlth, Med Oncol, Bendigo, Vic, Australia
[14] WEHI Walter & Eliza Hall Inst Med Res, Dept Oncol, Parkville, Vic, Australia
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.202
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
165P
引用
收藏
页码：S1498 / S1499
页数：2
相关论文
共 50 条
  • [21] The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis
    Mutlu, Hasan
    Bozcuk, Hakan
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (02) : 394 - 402
  • [22] Efficacy and tolerability of docetaxel chemotherapy in 'real-world' patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Maw, May Tun Hla
    Malik, Laeeq
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 127 - 127
  • [23] Triple therapy in metastatic hormone-sensitive prostate cancer
    Tsaur, Igor
    Mirvald, Cristian
    Surcel, Cristian
    [J]. CURRENT OPINION IN UROLOGY, 2023, 33 (06) : 452 - 457
  • [24] Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
    Isaksson, Jenny
    Green, Henrik
    Papantoniou, Dimitrios
    Pettersson, Linn
    Anden, Mats
    Rosell, Johan
    Avall-Lundqvist, Elisabeth
    Elander, Nils Oskar
    [J]. WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (11): : 1009 - 1022
  • [25] Systemic therapy in metastatic hormone-sensitive prostate cancer
    McDonald, Jodie
    O'Brien, Jonathan
    Kostos, Louise
    Lawrentschuk, Nathan
    Azad, Arun A.
    Murphy, Declan
    Chen, Kenneth
    [J]. CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2022, 16 (04) : 234 - 239
  • [26] COMPARISON OF UPFRONT ARAT THERAPY AND CAB THERAPY FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A RETROSPECTIVE MULTICENTER STUDY
    Shiraishi, Yusuke
    Tobe, Taisuke
    Ueki, Hideto
    Suzuki, Kotaro
    Hara, Takuto
    Terakawa, Tomoaki
    Teishima, Jun
    Nakano, Yuzo
    Miyake, Hideaki
    Fujisawa, Masato
    [J]. JOURNAL OF UROLOGY, 2024, 211 (05): : E1003 - E1004
  • [27] Metastatic hormone-sensitive prostate cancer
    Gravis, Gwenaelle
    Salem, Naji
    Walz, Jochen
    [J]. BULLETIN DU CANCER, 2015, 102 (01) : 57 - 64
  • [28] Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer
    Hindie, Elif
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3873 - 3875
  • [29] Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer
    Shiota, Masaki
    Eto, Masatoshi
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (05) : 360 - 369
  • [30] Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
    Kai Ozaki
    Shingo Hatakeyama
    Shintaro Narita
    Kenichi Hata
    Takafumi Yanagisawa
    Toshikazu Tanaka
    Kyo Togashi
    Tomoko Hamaya
    Teppei Okamoto
    Hayato Yamamoto
    Takahiro Yoneyama
    Yasuhiro Hashimoto
    Takahiro Kimura
    Tomonori Habuchi
    Chikara Ohyama
    [J]. World Journal of Urology, 2023, 41 : 67 - 75
12345